MX2020013719A - Nuevos compuestos heterociclicos como inhibidores de monoacilglicerol lipasa. - Google Patents
Nuevos compuestos heterociclicos como inhibidores de monoacilglicerol lipasa.Info
- Publication number
- MX2020013719A MX2020013719A MX2020013719A MX2020013719A MX2020013719A MX 2020013719 A MX2020013719 A MX 2020013719A MX 2020013719 A MX2020013719 A MX 2020013719A MX 2020013719 A MX2020013719 A MX 2020013719A MX 2020013719 A MX2020013719 A MX 2020013719A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- heterocyclic compounds
- new heterocyclic
- monoacylglycerol lipase
- lipase inhibitors
- Prior art date
Links
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 title abstract 3
- 108020002334 Monoacylglycerol lipase Proteins 0.000 title abstract 3
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 229940127470 Lipase Inhibitors Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención proporciona nuevos compuestos heterocíclicos que tienen la fórmula general (I) (ver Fórmula) en donde A, L, X, m, n, R1 y R2 son como se describen en el presente documento, composiciones que incluyen los compuestos, procesos de fabricación de los compuestos, métodos de uso de los compuestos y métodos para determinar la actividad inhibidora de monoacilglicerol lipasa (MAGL) de los compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18188679 | 2018-08-13 | ||
| PCT/EP2019/071522 WO2020035425A1 (en) | 2018-08-13 | 2019-08-12 | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013719A true MX2020013719A (es) | 2021-03-02 |
Family
ID=63244466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013719A MX2020013719A (es) | 2018-08-13 | 2019-08-12 | Nuevos compuestos heterociclicos como inhibidores de monoacilglicerol lipasa. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20210277020A1 (es) |
| EP (1) | EP3837264A1 (es) |
| JP (1) | JP2021533093A (es) |
| KR (1) | KR20210044217A (es) |
| CN (1) | CN112469724A (es) |
| AR (1) | AR115949A1 (es) |
| AU (1) | AU2019322161A1 (es) |
| BR (1) | BR112020025642A2 (es) |
| CA (1) | CA3098272A1 (es) |
| CL (1) | CL2021000361A1 (es) |
| CR (1) | CR20210056A (es) |
| IL (1) | IL280762A (es) |
| MA (1) | MA53220A (es) |
| MX (1) | MX2020013719A (es) |
| PE (1) | PE20211380A1 (es) |
| PH (1) | PH12021500015A1 (es) |
| SG (1) | SG11202012222TA (es) |
| TW (1) | TWI814882B (es) |
| WO (1) | WO2020035425A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| JP7269948B2 (ja) | 2017-11-28 | 2023-05-09 | エフ． ホフマン－ラ ロシュ アーゲー | 新規複素環式化合物 |
| JP7269943B2 (ja) | 2018-01-08 | 2023-05-09 | エフ． ホフマン－ラ ロシュ アーゲー | Ｍａｇｌ阻害剤としてのオクタヒドロピリド［１，２－アルファ］ピラジン |
| KR20200139153A (ko) | 2018-02-27 | 2020-12-11 | 인사이트 코포레이션 | A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘 |
| MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| JP7490631B2 (ja) | 2018-07-05 | 2024-05-27 | インサイト・コーポレイション | Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体 |
| JP7637049B2 (ja) | 2018-08-13 | 2025-02-27 | エフ． ホフマン－ラ ロシュ アーゲー | モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| CN114650994A (zh) * | 2019-09-12 | 2022-06-21 | 豪夫迈·罗氏有限公司 | 放射性标记的化合物 |
| EP4028403B1 (en) | 2019-09-12 | 2023-11-22 | F. Hoffmann-La Roche AG | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| MX2022003023A (es) * | 2019-09-23 | 2022-04-07 | Hoffmann La Roche | Compuestos heterociclicos. |
| AU2020356241A1 (en) * | 2019-09-24 | 2022-02-17 | F. Hoffmann-La Roche Ag | Heterocyclic compounds |
| US20210094973A1 (en) * | 2019-09-24 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| CR20230115A (es) | 2020-09-03 | 2023-04-11 | Hoffmann La Roche | Compuestos heterocíclicos |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| KR20250060956A (ko) | 2022-08-05 | 2025-05-07 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| FR2915197B1 (fr) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| EP2475667A1 (en) | 2009-09-10 | 2012-07-18 | F. Hoffmann-La Roche AG | Inhibitors of jak |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CA2854266A1 (en) * | 2011-11-30 | 2013-06-06 | Actelion Pharmaceuticals Ltd | 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics |
| JP6653319B2 (ja) * | 2015-03-30 | 2020-02-26 | 武田薬品工業株式会社 | 複素環化合物 |
| BR112017024678A2 (pt) | 2015-05-21 | 2018-07-31 | Glaxosmithkline Intellectual Property Development Limited | derivados de benzoimidazol como inibidores de pad4 |
| US10610520B2 (en) * | 2016-03-31 | 2020-04-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| KR102388440B1 (ko) * | 2016-03-31 | 2022-04-19 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로시클릭 화합물 |
-
2019
- 2019-08-12 SG SG11202012222TA patent/SG11202012222TA/en unknown
- 2019-08-12 CR CR20210056A patent/CR20210056A/es unknown
- 2019-08-12 EP EP19755856.2A patent/EP3837264A1/en not_active Withdrawn
- 2019-08-12 MA MA053220A patent/MA53220A/fr unknown
- 2019-08-12 CN CN201980048654.2A patent/CN112469724A/zh active Pending
- 2019-08-12 BR BR112020025642-0A patent/BR112020025642A2/pt unknown
- 2019-08-12 CA CA3098272A patent/CA3098272A1/en active Pending
- 2019-08-12 WO PCT/EP2019/071522 patent/WO2020035425A1/en not_active Application Discontinuation
- 2019-08-12 PE PE2020002021A patent/PE20211380A1/es unknown
- 2019-08-12 AU AU2019322161A patent/AU2019322161A1/en not_active Abandoned
- 2019-08-12 KR KR1020217004224A patent/KR20210044217A/ko not_active Ceased
- 2019-08-12 JP JP2021503816A patent/JP2021533093A/ja active Pending
- 2019-08-12 MX MX2020013719A patent/MX2020013719A/es unknown
- 2019-08-13 AR ARP190102302A patent/AR115949A1/es not_active Application Discontinuation
- 2019-08-13 TW TW108128684A patent/TWI814882B/zh not_active IP Right Cessation
-
2021
- 2021-02-09 IL IL280762A patent/IL280762A/en unknown
- 2021-02-10 CL CL2021000361A patent/CL2021000361A1/es unknown
- 2021-02-11 PH PH12021500015A patent/PH12021500015A1/en unknown
- 2021-02-11 US US17/174,000 patent/US20210277020A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210277020A1 (en) | 2021-09-09 |
| EP3837264A1 (en) | 2021-06-23 |
| SG11202012222TA (en) | 2021-01-28 |
| KR20210044217A (ko) | 2021-04-22 |
| CN112469724A (zh) | 2021-03-09 |
| WO2020035425A1 (en) | 2020-02-20 |
| CR20210056A (es) | 2021-03-02 |
| IL280762A (en) | 2021-04-29 |
| AU2019322161A1 (en) | 2020-11-12 |
| MA53220A (fr) | 2021-11-17 |
| JP2021533093A (ja) | 2021-12-02 |
| AR115949A1 (es) | 2021-03-17 |
| TWI814882B (zh) | 2023-09-11 |
| BR112020025642A2 (pt) | 2021-03-23 |
| CA3098272A1 (en) | 2020-02-20 |
| PH12021500015A1 (en) | 2021-09-13 |
| TW202035421A (zh) | 2020-10-01 |
| CL2021000361A1 (es) | 2021-07-09 |
| PE20211380A1 (es) | 2021-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021500015A1 (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| PH12021500013A1 (en) | New heterocyclic compounds as monoacylgylcerol lipase inhibitors | |
| PH12021551167A1 (en) | New heterocyclic compounds | |
| PH12020500661A1 (en) | Oxazine monoacylglycerol lipase (magl) inhibitors | |
| PH12022550472A1 (en) | New heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| PH12022550339A1 (en) | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors | |
| PH12022550321A1 (en) | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors | |
| BR112018006080A2 (pt) | novos compostos bicíclicos como inibidores de dupla ação de atx/ca | |
| MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
| PH12022550471A1 (en) | Heterocyclic compounds | |
| MX2022000243A (es) | Nuevos compuestos heterociclicos. | |
| PH12019500664B1 (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
| WO2019231933A3 (en) | Masp-2 inhibitors and methods of use | |
| PH12022550433A1 (en) | Heterocyclic compounds | |
| MX2022006750A (es) | Inhibidores de masp-2 y metodos de uso. | |
| MX2020013630A (es) | Analogos de rapamicina y usos de los mismos. | |
| PH12021550320A1 (en) | Bicyclic heteroaryl derivatives | |
| EA202192237A1 (ru) | Кристаллические формы ингибитора jak2 | |
| PH12018500407A1 (en) | New bicyclic compounds as dual atx/ca inhibitors | |
| PH12018500406A1 (en) | Bicyclic compounds as atx inhibitors |